Sophie McGrath is a partner in Goodwin’s Technology and Life Sciences group. Ms. McGrath focuses on transactions in the life sciences and technology sectors, acting for companies at all stages of development, as well as investors and management teams. She advises on a wide range of corporate matters, including private and public financings, mergers and acquisitions, public offerings and restructurings.

Ms. McGrath also has a keen interest in the impact investment sector, acting for both investors and companies that are targeting a “double bottom line,” either through environmental or social impact, and is a member of the British Venture Capital Association’s Impact Investment advisory group, which has a mandate to promote the development of the impact investment sector in the UK.

Ms. McGrath is a recommended lawyer for Venture Capital and M&A in the Legal 500 UK and was nominated for the “Corporate - Rising Star” Award at the 2013 Euromoney Women in Business Law Awards.

Prior to joining Goodwin in 2018, Ms. McGrath was a partner at Brown Rudnick.





  • Advised Quanta Dialysis Technologies Limited, a medical device company focused on haemodialysis systems for use in the clinic and home, on the first closing of its series C funding round raising over £38 million.
  • Advised N+1 Singer as nominated adviser and broker to Verona Pharma plc, a listed drug development company, in relation to its £44.7 million UK and U.S. placing.*
  • Advised a listed life sciences company in relation to its acquisition of a medical devices business based in the U.S.*
  • Advised Cruncher Technologies Limited, a company using artificial intelligence to solve big data issues for the financial markets, on various financing rounds and its commercialisation into the U.S.*
  • Advised Neuroprotexeon Limited, a late clinical-stage pharmaceutical and medical device company, on its initial spinout from Imperial College London, subsequent rounds of private financing and issues relating to the cross border nature of its operations.*
  • Advised Gilde Healthcare Partners B.V. as lead investor on multiple financing rounds into Qinec Limited, a digital healthcare company.*
  • Advised Mustard Seed, an impact investment fund, on multiple investments including:*
    • Skin Healthcare, a skin analytics app and device designed to help identify early signs of skin cancer
    • Beulah, a luxury goods company providing employment opportunities to victims of human trafficking
    • Switchee, a company seeking to significantly reduce energy use and spending
  • Advised Novo A/S, Lundbeckfond A/S and Gilde Heathcare Partners B.V. on multiple financing rounds into Acacia Pharma Limited, a specialty pharmaceutical company focused on the development and commercialisation of new treatments for the conditions arising as a consequence of surgery, cancer or cancer treatment.*
  • Advised Arc Medical Limited, a UK medical devices company, on a partial exit by certain shareholders to Norgine Ventures, along with a strategic investment and working capital facility from Norgine.*
  • Advised EQ Investors, a B Corporation certified wealth manager (B Corporations are for-profit companies certified as meeting rigorous standards of social and environmental performance, accountability, and transparency), in relation to the acquisition of Truestone Wealth Management, a financial planning firm with £500 million of client assets under management.*
  • Advised a European consortium of healthcare investors including Wellington Partners, Seroba Kernel, NBGI Ventures and B2V in relation to a £27 million Series B financing round into Quanta Fluid Solutions, a medical device company focused on haemodialysis systems for use in the clinic and home.*
  • Advised Novo A/S on a €100 million investment in Symphogen A/S, a Danish biotech company that specialises in the development of recombinant antibody therapies for the treatment and prevention of disease.*

* Denotes experience prior to joining Goodwin.

Professional Activities

British Venture Capital Association


Ms. McGrath has extensive experience in private investment work, acting for companies at all stages of development, as well as investors and management teams. She is a recommended lawyer in Legal 500 2017 in the fields of M&A: Smaller Deals, up to £50 million, where she is described as “very easy to work with” “sensible and pragmatic.”

Ms. McGrath is recommended in the Legal 500 2017 for Venture Capital and is described as “very resourceful and knowledgeable.”

She was recommended in the Legal 500 2016 for Venture Capital and is described as providing “an excellent all-round service” to clients active in the life sciences, technology and cleantech sectors.

Recommended as a leading lawyer for Venture Capital, and Pharmaceuticals and Biotechnology in the Legal 500 UK 2015.

Nominated for the “Corporate - Rising Star” Award at the 2013 Euromoney Women in Business Law Awards

In The News









Qualified Lawyers Transfer Test, 2003
College of Law London
Graduate Diploma in Law, 1999
College of Law, Sydney
Bachelors in Commerce and Laws, 1998
University of Sydney



Solicitor of the Senior Courts of England and Wales
New South Wales, Australia
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique